Transcript the slide set

HYVET 1-year extension: Immediate and late benefits with
indapamide SR ± perindopril in the treatment of hypertensive patients.
Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension:
results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial BMJ.
2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
HYVET 1-year extension1
Study protocol
2.1 years
1-year extension
Indapamide SR
± perindopril
Indapamide SR
± perindopril
Placebo
3.1 years on
active treatment
vs.
Placebo
n= 3845 patients
Indapamide SR
± perindopril
n= 1712 patients
1 year on
active treatment
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
HYVET 1
Results
2.1 years
Indapamide SR
± perindopril
Placebo
vs.
Placebo
n= 3845 patients
1. Beckett NS, Peters R, Fletcher AE, et al. N Engl J Med. 2008;358:1887-1898.
Stroke
hazard ratio: -39% P =0.05 in favor of the
indapamide SR ± perindopril group.
Heart failure
hazard ratio: -64% P<0.001 in favor of the
indapamide SR ± perindopril group.
Cardiovascular events
hazard ratio: -34% P<0.001 in favor of the
indapamide SR ± perindopril group.
Cardiovascular mortality
hazard ratio: -23% P=0.06 in favor of the
indapamide SR ± perindopril group.
All-cause mortality
hazard ratio: -21% P=0.02 in favor of the
indapamide SR ± perindopril group.
HYVET 1-year extension1
Study protocol
2.1 years
1-year extension
Indapamide SR
± perindopril
Indapamide SR
± perindopril
3.1 years on
active treatment
vs.
Placebo
Placebo
n= 3845 patients
Indapamide SR
± perindopril
n= 1712 patients
1 year on
active treatment
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
HYVET 1-year extension1
Results
2.1 years
1-year extension
Indapamide SR
± perindopril
Indapamide SR
± perindopril
vs.
Placebo
Placebo
n= 3845 patients
•
•
Indapamide SR
± perindopril
No significant difference
between the two arms in:
- Stroke P=0.28
- Heart failure P=0.28
- Cardiovascular events P=0.55
n= 1712 patients
Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart
failure, and cardiovascular events
These benefits appeared within 1 year of starting treatment
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
HYVET 1-year extension1
Results
2.1 years
1-year extension
Indapamide SR
± perindopril
Indapamide SR
± perindopril
vs.
Placebo
Placebo
n= 3845 patients
•
Indapamide SR
± perindopril
n= 1712 patients
Total mortality
hazard ratio: -52% P =0.02
in favor of the group treated for
3.1 years.
Cardiovascular mortality
hazard ratio: -81% P =0.03
in favor of the group treated for
3.1 years.
Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased
over the long term.
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
HYVET 1-year extension1
Results
Total mortality
Cardiovascular mortality
P=0.02
-52%
P=0.03
-81%
•
Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased
over the long term.
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)